They released stats on shares available yesterday.
The Lincoln deal is still on and won't be any different than it used to be.
I bet they have something up their sleeve or they wouldn't have uplisted.
Selling on the eve of trial results that will make medical history because of a RS is dumb.
I'm going to laugh if two or three weeks from this sits at $10+
Buyout will come will before commercialization. Plus they'll need a business partnership or big $$$ to get to the Nasdaq.
When they're on the Nasdaq, the big dilutive days are done.
We have a fresh CEO who left a great opportunity to come to ACTC. Trial results are imminent, with a probable partnership or financing deal coming soon since having around $35M is going to be a pre-req for the Nasdaq.
Paul and the team would not be uplisting if the time wasn't right. They may not have announced anything immediately last night, but I highly suspect that the news they have prepared to send out will counter any selling from skeptical investors that are taking a risk by selling today.
If folks sell this morning, this will be a great buying opportunity.
They need to happen in unison. NEJM is released on Wednesday. ACTC needs to coordinate the publish date and perform a RS around that time. Problem solved. The issue here is that ACTC promised to deliver amazing news and reverse split from a position of strength. It was supposed to be a singular event - strong foundation, positive science results, and a R/S with an uplist to Nasdaq. They failed to deliver.
The reason why so many here are disappointed is because we were told a R/S would not be performed without amazing, positive news to back it up.
As disappointed as I am that the R/S announcement was not coupled with tremendous news as promised by ACTC, the timeline for trial results pins the journal to be released between now and the next few weeks. If anything, a fall tomorrow, if it occurs, would present a good buying opportunity.
No news besides the RS. Management assured us this would be a singular event, and done from a position of strength. While we still may very well see long-term gains once we finally see results, this is the worst execution possible, IMO. I would still expect to see very good news in the near future.
August 27, 2014 05:12 PM Eastern Daylight Time
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that it has completed a 1:100 reverse split of its common stock.
“Completing this reverse stock split is an important step in our plan to improve our corporate structure and establish ACT as a highly-regarded, publicly-traded biotechnology company. With continued progress in many of our clinical and pre-clinical programs, the Lincoln Park equity facility in place and Dr. Wotton’s arrival as CEO, this initiative is part of a larger strategy to up-list to a national stock exchange and to raise awareness and visibility with fundamental-based, institutional biotech investors,” said Ted Myles, ACT’s Chief Financial Officer and Chief Operating Officer.
As a result of the reverse stock split, every 100 shares of the Company’s pre-reverse stock split common stock were combined and reclassified into one share of the Company’s common stock. Beginning with the opening of trading on August 28, 2014, the Company’s common stock will trade on the OTC Markets Group on a reverse stock split adjusted basis.
More information is available in ACT's Current Report on Form 8-K, filed today with the SEC.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., (ACT) is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technology. The company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration, Stargardt’s macular degeneration and myopic macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company’s intellectual property portfolio includes pluripotent stem
Market cap and number of available shares determine PPS. Market cap will increase to the appropriate level regardless of PPS. Therefore the percentage gains would as well.
I certainly hope management has something for us. Poor execution of the most pivotal milestones in the company's history shouldn't be tolerated. They need to take into consideration timing, market reaction, media coverage, and other factors.
No, I'm not comparing company to company. I'm giving you examples of SITUATIONS where a reverse split can be beneficial... Such as what ACTC is working towards - uplisting to a national exchange and bringing in MILLIONS of dollars of additional investors and institutions.
MultiStem? For real? ATHX posted extremely disappointing trial results and is getting closer and closer to getting to the critical $1 point on the Nasdaq. Expect the company to do a forced reverse split with dilution.